{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:45:53Z","timestamp":1788353153509,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,12,9]],"date-time":"2016-12-09T00:00:00Z","timestamp":1481241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,12,9]],"date-time":"2016-12-09T00:00:00Z","timestamp":1481241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Gouty arthritis is caused by the deposition of uric acid crystals, which induce the activation of NOD-like receptor family, pyrin domain containing 3(NLRP3) inflammasome. The NLRP3 inflammasome, composed of NLRP3, the adaptor protein ASC, and caspase-1, is closely linked to the pathogenesis of various metabolic diseases including gouty arthritis. We investigated whether an orally administrable inhibitor of NLRP3 inflammasome was effective for alleviating the pathological symptoms of gouty arthritis and what was the underlying mechanism. In primary mouse macrophages, caffeic acid phenethyl ester(CAPE) blocked caspase-1 activation and IL-1\u03b2 production induced by MSU crystals, showing that CAPE suppresses NLRP3 inflammasome activation. In mouse gouty arthritis models, oral administration of CAPE suppressed MSU crystals-induced caspase-1 activation and IL-1\u03b2 production in the air pouch exudates and the foot tissues, correlating with attenuation of inflammatory symptoms. CAPE directly associated with ASC as shown by SPR analysis and co-precipitation, resulting in blockade of NLRP3-ASC interaction induced by MSU crystals. Our findings provide a novel regulatory mechanism by which small molecules harness the activation of NLRP3 inflammasome by presenting ASC as a new target. Furthermore, the results suggest the preventive or therapeutic strategy for NLRP3-related inflammatory diseases such as gouty arthritis using orally available small molecules.<\/jats:p>","DOI":"10.1038\/srep38622","type":"journal-article","created":{"date-parts":[[2016,12,9]],"date-time":"2016-12-09T12:44:25Z","timestamp":1481287465000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":103,"title":["Targeting ASC in NLRP3 inflammasome by caffeic acid phenethyl ester: a novel strategy to treat acute gout"],"prefix":"10.1038","volume":"6","author":[{"given":"Hye Eun","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabsik","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nam Doo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seongkeun","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunjin","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Young","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Ho","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,12,9]]},"reference":[{"key":"BFsrep38622_CR1","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1002\/art.30520","volume":"63","author":"Y Zhu","year":"2011","unstructured":"Zhu, Y., Pandya, B. J. & Choi, H. K. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007\u20132008. Arthritis Rheum 63, 3136\u20133141, doi: 10.1002\/art.30520 (2011).","journal-title":"Arthritis Rheum"},{"key":"BFsrep38622_CR2","doi-asserted-by":"publisher","first-page":"165","DOI":"10.7326\/0003-4819-115-3-165","volume":"115","author":"DP Sandler","year":"1991","unstructured":"Sandler, D. P., Burr, F. R. & Weinberg, C. R. Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. Ann Intern Med 115, 165\u2013172 (1991).","journal-title":"Ann Intern Med"},{"key":"BFsrep38622_CR3","doi-asserted-by":"publisher","first-page":"R28","DOI":"10.1186\/ar2143","volume":"9","author":"A So","year":"2007","unstructured":"So, A., De Smedt, T., Revaz, S. & Tschopp, J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 9, R28, doi: 10.1186\/ar2143 (2007).","journal-title":"Arthritis Res Ther"},{"key":"BFsrep38622_CR4","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1097\/bor.0000000000000143","volume":"27","author":"A Dumusc","year":"2015","unstructured":"Dumusc, A. & So, A. Interleukin-1 as a therapeutic target in gout. Curr Opin Rheumatol 27, 156\u2013163, doi: 10.1097\/bor.0000000000000143 (2015).","journal-title":"Curr Opin Rheumatol"},{"key":"BFsrep38622_CR5","doi-asserted-by":"publisher","first-page":"452","DOI":"10.7326\/0003-4819-54-3-452","volume":"54","author":"DJ McCarty","year":"1961","unstructured":"McCarty, D. J. & Hollander, J. L. Identification of urate crystals in gouty synovial fluid. Ann Intern Med 54, 452\u2013460 (1961).","journal-title":"Ann Intern Med"},{"key":"BFsrep38622_CR6","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/ar3199","volume":"12","author":"E Roddy","year":"2010","unstructured":"Roddy, E. & Doherty, M. Epidemiology of gout. Arthritis Res Ther 12, 223, doi: 10.1186\/ar3199 (2010).","journal-title":"Arthritis Res Ther"},{"key":"BFsrep38622_CR7","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nature04516","volume":"440","author":"F Martinon","year":"2006","unstructured":"Martinon, F., Petrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237\u2013241, doi: 10.1038\/nature04516 (2006).","journal-title":"Nature"},{"key":"BFsrep38622_CR8","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1002\/art.33355","volume":"64","author":"FA Amaral","year":"2012","unstructured":"Amaral, F. A. et al. NLRP3 inflammasome-mediated neutrophil recruitment and hypernociception depend on leukotriene B(4) in a murine model of gout. Arthritis Rheum 64, 474\u2013484, doi: 10.1002\/art.33355 (2012).","journal-title":"Arthritis Rheum"},{"key":"BFsrep38622_CR9","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1111\/bph.12091","volume":"168","author":"SY Kim","year":"2013","unstructured":"Kim, S. Y. et al. Suppression of Toll-like receptor 4 activation by caffeic acid phenethyl ester is mediated by interference of LPS binding to MD2. Br J Pharmacol 168, 1933\u20131945, doi: 10.1111\/bph.12091 (2013).","journal-title":"Br J Pharmacol"},{"key":"BFsrep38622_CR10","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1038\/sj.cdd.4402194","volume":"14","author":"T Fernandes-Alnemri","year":"2007","unstructured":"Fernandes-Alnemri, T. et al. The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation. Cell Death Differ 14, 1590\u20131604, doi: 10.1038\/sj.cdd.4402194 (2007).","journal-title":"Cell Death Differ"},{"key":"BFsrep38622_CR11","doi-asserted-by":"publisher","first-page":"5071","DOI":"10.1038\/sj.emboj.7601378","volume":"25","author":"P Pelegrin","year":"2006","unstructured":"Pelegrin, P. & Surprenant, A. Pannexin-1 mediates large pore formation and interleukin-1beta release by the ATP-gated P2X7 receptor. Embo j 25, 5071\u20135082, doi: 10.1038\/sj.emboj.7601378 (2006).","journal-title":"Embo j"},{"key":"BFsrep38622_CR12","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.cell.2006.07.033","volume":"126","author":"L Gurcel","year":"2006","unstructured":"Gurcel, L., Abrami, L., Girardin, S., Tschopp, J. & van der Goot, F. G. Caspase-1 activation of lipid metabolic pathways in response to bacterial pore-forming toxins promotes cell survival. Cell 126, 1135\u20131145, doi: 10.1016\/j.cell.2006.07.033 (2006).","journal-title":"Cell"},{"key":"BFsrep38622_CR13","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/nmeth.2327","volume":"10","author":"E Bartok","year":"2013","unstructured":"Bartok, E. et al. iGLuc: a luciferase-based inflammasome and protease activity reporter. Nat Methods 10, 147\u2013154, doi: 10.1038\/nmeth.2327 (2013).","journal-title":"Nat Methods"},{"key":"BFsrep38622_CR14","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/nature07725","volume":"458","author":"V Hornung","year":"2009","unstructured":"Hornung, V. et al. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 458, 514\u2013518, doi: 10.1038\/nature07725 (2009).","journal-title":"Nature"},{"key":"BFsrep38622_CR15","doi-asserted-by":"publisher","first-page":"32932","DOI":"10.1074\/jbc.M109.024273","volume":"284","author":"E de Alba","year":"2009","unstructured":"de Alba, E. Structure and interdomain dynamics of apoptosis-associated speck-like protein containing a CARD (ASC). J Biol Chem 284, 32932\u201332941, doi: 10.1074\/jbc.M109.024273 (2009).","journal-title":"J Biol Chem"},{"key":"BFsrep38622_CR16","doi-asserted-by":"publisher","first-page":"23504","DOI":"10.1074\/jbc.M114.553305","volume":"289","author":"PR Vajjhala","year":"2014","unstructured":"Vajjhala, P. R. et al. Identification of multifaceted binding modes for pyrin and ASC pyrin domains gives insights into pyrin inflammasome assembly. J Biol Chem 289, 23504\u201323519, doi: 10.1074\/jbc.M114.553305 (2014).","journal-title":"J Biol Chem"},{"key":"BFsrep38622_CR17","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1016\/j.str.2014.09.011","volume":"22","author":"AC Sahillioglu","year":"2014","unstructured":"Sahillioglu, A. C., Sumbul, F., Ozoren, N. & Haliloglu, T. Structural and dynamics aspects of ASC speck assembly. Structure 22, 1722\u20131734, doi: 10.1016\/j.str.2014.09.011 (2014).","journal-title":"Structure"},{"key":"BFsrep38622_CR18","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1164\/rccm.200808-1274OC","volume":"179","author":"P Gasse","year":"2009","unstructured":"Gasse, P. et al. Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis. Am J Respir Crit Care Med 179, 903\u2013913, doi: 10.1164\/rccm.200808-1274OC (2009).","journal-title":"Am J Respir Crit Care Med"},{"key":"BFsrep38622_CR19","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.metabol.2014.02.003","volume":"63","author":"SJ Yang","year":"2014","unstructured":"Yang, S. J. & Lim, Y. Resveratrol ameliorates hepatic metaflammation and inhibits NLRP3 inflammasome activation. Metabolism 63, 693\u2013701, doi: 10.1016\/j.metabol.2014.02.003 (2014).","journal-title":"Metabolism"},{"key":"BFsrep38622_CR20","doi-asserted-by":"publisher","first-page":"e38285","DOI":"10.1371\/journal.pone.0038285","volume":"7","author":"C Wang","year":"2012","unstructured":"Wang, C., Pan, Y., Zhang, Q. Y., Wang, F. M. & Kong, L. D. Quercetin and allopurinol ameliorate kidney injury in STZ-treated rats with regulation of renal NLRP3 inflammasome activation and lipid accumulation. PLoS One 7, e38285, doi: 10.1371\/journal.pone.0038285 (2012).","journal-title":"PLoS One"},{"key":"BFsrep38622_CR21","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.freeradbiomed.2011.05.016","volume":"51","author":"PY Tsai","year":"2011","unstructured":"Tsai, P. Y. et al. Epigallocatechin-3-gallate prevents lupus nephritis development in mice via enhancing the Nrf2 antioxidant pathway and inhibiting NLRP3 inflammasome activation. Free Radic Biol Med 51, 744\u2013754, doi: 10.1016\/j.freeradbiomed.2011.05.016 (2011).","journal-title":"Free Radic Biol Med"},{"key":"BFsrep38622_CR22","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1074\/jbc.M113.515080","volume":"289","author":"Y He","year":"2014","unstructured":"He, Y. et al. 3,4-methylenedioxy-beta-nitrostyrene inhibits NLRP3 inflammasome activation by blocking assembly of the inflammasome. J Biol Chem 289, 1142\u20131150, doi: 10.1074\/jbc.M113.515080 (2014).","journal-title":"J Biol Chem"},{"key":"BFsrep38622_CR23","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nm.3806","volume":"21","author":"RC Coll","year":"2015","unstructured":"Coll, R. C. et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med 21, 248\u2013255, doi: 10.1038\/nm.3806 (2015).","journal-title":"Nat Med"},{"key":"BFsrep38622_CR24","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/nm.3804","volume":"21","author":"YH Youm","year":"2015","unstructured":"Youm, Y. H. et al. The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med 21, 263\u2013269, doi: 10.1038\/nm.3804 (2015).","journal-title":"Nat Med"},{"key":"BFsrep38622_CR25","doi-asserted-by":"publisher","first-page":"499","DOI":"10.4049\/jimmunol.0903534","volume":"186","author":"SM Joung","year":"2011","unstructured":"Joung, S. M. et al. Akt contributes to activation of the TRIF-dependent signaling pathways of TLRs by interacting with TANK-binding kinase 1. J Immunol 186, 499\u2013507, doi: 10.4049\/jimmunol.0903534 (2011).","journal-title":"J Immunol"},{"key":"BFsrep38622_CR26","doi-asserted-by":"publisher","first-page":"4846","DOI":"10.1128\/mcb.00494-12","volume":"32","author":"SD Ha","year":"2012","unstructured":"Ha, S. D., Park, S., Han, C. Y., Nguyen, M. L. & Kim, S. O. Cellular adaptation to anthrax lethal toxin-induced mitochondrial cholesterol enrichment, hyperpolarization, and reactive oxygen species generation through downregulating MLN64 in macrophages. Mol Cell Biol 32, 4846\u20134860, doi: 10.1128\/mcb.00494-12 (2012).","journal-title":"Mol Cell Biol"},{"key":"BFsrep38622_CR27","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.jnutbio.2009.06.002","volume":"21","author":"D Choi","year":"2010","unstructured":"Choi, D. et al. Caffeic acid phenethyl ester is a potent inhibitor of HIF prolyl hydroxylase: structural analysis and pharmacological implication. J Nutr Biochem 21, 809\u2013817, doi: 10.1016\/j.jnutbio.2009.06.002 (2010).","journal-title":"J Nutr Biochem"},{"key":"BFsrep38622_CR28","doi-asserted-by":"publisher","first-page":"24399","DOI":"10.1038\/srep24399","volume":"6","author":"G Yang","year":"2016","unstructured":"Yang, G., Lee, H. E. & Lee, J. Y. A pharmacological inhibitor of NLRP3 inflammasome prevents non-alcoholic fatty liver disease in a mouse model induced by high fat diet. Sci Rep 6, 24399, doi: 10.1038\/srep24399 (2016).","journal-title":"Sci Rep"},{"key":"BFsrep38622_CR29","doi-asserted-by":"crossref","unstructured":"Yeon, S. H., Yang, G., Lee, H. E. & Lee, J. Y. Oxidized phosphatidylcholine induces the activation of NLRP3 inflammasome in macrophages. J Leukoc Biol, doi: 10.1189\/jlb.3VMA1215-579RR (2016).","DOI":"10.1189\/jlb.3VMA1215-579RR"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep38622.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep38622","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep38622.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T03:50:32Z","timestamp":1672890632000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep38622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,9]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12,23]]}},"alternative-id":["BFsrep38622"],"URL":"https:\/\/doi.org\/10.1038\/srep38622","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,9]]},"assertion":[{"value":"26 August 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38622"}}